Literature DB >> 15886263

Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei.

Vanaporn Wuthiekanun1, Allen C Cheng, Wirongrong Chierakul, Premjit Amornchai, Direk Limmathurotsakul, Wipada Chaowagul, Andrew J H Simpson, Jennifer M Short, Gumphol Wongsuvan, Bina Maharjan, Nicholas J White, Sharon J Peacock.   

Abstract

OBJECTIVES: Trimethoprim/sulfamethoxazole is commonly used to treat melioidosis. Antimicrobial susceptibility testing using the disc diffusion method is commonly used in melioidosis-endemic areas, but may overestimate resistance to trimethoprim/sulfamethoxazole. PATIENTS AND METHODS: We performed disc diffusion and Etest on isolates from the first positive culture for all patients presenting to Sappasithiprasong Hospital, Ubon Ratchathani, Thailand, with culture-confirmed melioidosis between 1992 and 2003.
RESULTS: The estimated resistance rate for 1976 clinical Burkholderia pseudomallei isolates was 13% by Etest and 71% by disc diffusion. All isolates classed as either susceptible (n=358) or as having intermediate resistance (n=218) on disc diffusion were susceptible by Etest. Only 258 of the 1400 (18%) isolates classed as resistant on disc diffusion were resistant by Etest.
CONCLUSIONS: Disc diffusion testing of B. pseudomallei may be useful as a limited screening tool in resource poor settings. Isolates assigned as 'susceptible' or 'intermediate' by disc diffusion may be viewed as 'susceptible'; those assigned as 'resistant' require further evaluation by MIC methodology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15886263     DOI: 10.1093/jac/dki151

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  37 in total

1.  In vitro activity of doripenem against Burkholderia pseudomallei.

Authors:  Visanu Thamlikitkul; Suwanna Trakulsomboon
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

Review 2.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

3.  Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand.

Authors:  Vanaporn Wuthiekanun; Premjit Amornchai; Natnaree Saiprom; Narisara Chantratita; Wirongrong Chierakul; Gavin C K W Koh; Wipada Chaowagul; Nicholas P J Day; Direk Limmathurotsakul; Sharon J Peacock
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

4.  Development and validation of a triplex quantitative real-time PCR assay to detect efflux pump-mediated antibiotic resistance in Burkholderia pseudomallei.

Authors:  Jessica R Webb; Erin P Price; Nawarat Somprasong; Herbert P Schweizer; Robert W Baird; Bart J Currie; Derek S Sarovich
Journal:  Future Microbiol       Date:  2018-09-26       Impact factor: 3.165

5.  Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis.

Authors:  Wipada Chaowagul; Wirongrong Chierakul; Andrew J Simpson; Jennifer M Short; Kasia Stepniewska; Bina Maharjan; Adul Rajchanuvong; Duangkaew Busarawong; Direk Limmathurotsakul; Allen C Cheng; Vanaporn Wuthiekanun; Paul N Newton; Nicholas J White; Nicholas P J Day; Sharon J Peacock
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

6.  In vitro activity of tigecycline against Burkholderia pseudomallei and Burkholderia thailandensis.

Authors:  Visanu Thamlikitkul; Suwanna Trakulsomboon
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  A Burkholderia pseudomallei Infection Imported from Eritrea to Israel.

Authors:  Yaniv Almog; Yael Yagel; Yuval Geffen; Pablo Yagupsky
Journal:  Am J Trop Med Hyg       Date:  2016-08-29       Impact factor: 2.345

8.  Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei.

Authors:  Sharon J Peacock; Herbert P Schweizer; David A B Dance; Theresa L Smith; Jay E Gee; Vanaporn Wuthiekanun; David DeShazer; Ivo Steinmetz; Patrick Tan; Bart J Currie
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

9.  Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis.

Authors:  Allen C Cheng; Emma S McBryde; Vanaporn Wuthiekanun; Wirongrong Chierakul; Premjit Amornchai; Nicholas P J Day; Nicholas J White; Sharon J Peacock
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

Review 10.  Burkholderia pseudomallei: Challenges for the Clinical Microbiology Laboratory.

Authors:  Peera Hemarajata; Jonathan D Baghdadi; Risa Hoffman; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2016-09-21       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.